Leerink Partnrs Predicts Lower Earnings for Tourmaline Bio

Tourmaline Bio, Inc. (NASDAQ:TRML) – Stock analysts at Leerink Partnrs lowered their FY2025 EPS estimates for shares of Tourmaline Bio in a report issued on Monday, May 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($3.71) for the year, down from their previous estimate of ($3.22). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.28) EPS, FY2027 earnings at ($5.89) EPS, FY2028 earnings at ($6.73) EPS and FY2029 earnings at ($3.45) EPS.

A number of other analysts have also recently commented on the company. Lifesci Capital began coverage on Tourmaline Bio in a research report on Monday, February 24th. They set an “outperform” rating and a $58.00 price objective for the company. Chardan Capital reissued a “buy” rating and issued a $70.00 price objective on shares of Tourmaline Bio in a research report on Monday, May 5th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Tourmaline Bio in a research report on Monday, May 5th. Finally, Wedbush boosted their price target on Tourmaline Bio from $42.00 to $43.00 and gave the company an “outperform” rating in a report on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $49.33.

Tourmaline Bio Stock Performance

Tourmaline Bio stock opened at $15.09 on Thursday. Tourmaline Bio has a fifty-two week low of $11.56 and a fifty-two week high of $29.79. The company has a market capitalization of $387.59 million, a price-to-earnings ratio of -5.35 and a beta of 2.11. The stock has a fifty day moving average of $15.49 and a two-hundred day moving average of $18.78.

Tourmaline Bio (NASDAQ:TRML) last issued its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.02.

Institutional Trading of Tourmaline Bio

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Tourmaline Bio by 7.7% in the 1st quarter. Vanguard Group Inc. now owns 1,190,810 shares of the company’s stock worth $18,112,000 after buying an additional 84,685 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Tourmaline Bio in the 4th quarter worth about $12,168,000. Velan Capital Investment Management LP lifted its stake in shares of Tourmaline Bio by 28.0% in the 4th quarter. Velan Capital Investment Management LP now owns 423,795 shares of the company’s stock valued at $8,595,000 after purchasing an additional 92,605 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of Tourmaline Bio by 69.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company’s stock worth $8,515,000 after purchasing an additional 172,743 shares during the period. Finally, Acuta Capital Partners LLC increased its position in Tourmaline Bio by 5.9% during the 4th quarter. Acuta Capital Partners LLC now owns 351,842 shares of the company’s stock worth $7,135,000 after purchasing an additional 19,747 shares in the last quarter. 91.89% of the stock is owned by hedge funds and other institutional investors.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.